comparemela.com

Latest Breaking News On - Interim analysis - Page 6 : comparemela.com

Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia.

China
United-kingdom
Amsterdam
Noord-holland
Netherlands
Canada
Japan
Israel
Phoenix
Arizona
United-states
American

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini.

China
Amsterdam
Noord-holland
Netherlands
United-states
Japan
Phoenix
Arizona
Canada
Israel
United-kingdom
American

Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
New-york
Wynn-las-vegas
Ido-weinberg
Marianne-brodmann
Williama-gray
D-christopher-metzger
Concept-medical-inc
European-union
Pp-new-york-heart-association
Philips
Indigo-aspiration-system-penumbra-inc

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial. Treatment with the drug candidate, acquired as part of the purchase of U.S. biotech firm Chinook Therapeutics for up to $3.5 billion, resulted in a clinically meaningful improvement in kidney filtration in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement.

Switzerland
Frankfurt
Brandenburg
Germany
Swiss
Ludwig-burger
Friederike-heine
Novartis
Drug-administration
Chinook-therapeutics
Kidney-function
Drug-candidate

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

Annovis Bio, Inc. , a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease ,.

Massachusetts
United-states
Berwyn
Pennsylvania
Boston
Annovis-bio
Cheng-fang
Exchange-commission
Annovis-bio-inc
Twitter
Linkedin
Clinical-trials

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.